RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia

Pharmacogenomics

Volumn 16, Issue 8, 2015, Pages 877-890

  Abraham, Ajay ^a   Varatharajan, Savitha ^a   Karathedath, Sreeja ^a   Philip, Chepsy ^a   Lakshmi, Kavitha M ^a   Jayavelu, Ashok Kumar ^a   Mohanan, Ezhilpavai ^a   Janet, Nancy Beryl ^a   Srivastava, Vivi M ^a   Shaji, Ramachandran V ^a   Zhang, Wei ^b   Abraham, Aby ^a   Viswabandya, Auro ^a   George, Biju ^a   Chandy, Mammen ^a   Srivastava, Alok ^a   Mathews, Vikram ^a   Balasubramanian, Poonkuzhali ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

acute myeloid leukemia; cytarabine; drug resistance

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RIBONUCLEOTIDE REDUCTASE; RNA; ANTINEOPLASTIC ANTIMETABOLITE; RRM1 PROTEIN, HUMAN; SLC29A1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DCK GENE; DRUG METABOLISM; DRUG RESPONSE; EX VIVO STUDY; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IC50; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MTT ASSAY; POLYMERASE CHAIN REACTION; RRM1 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ARA;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS;

EID: 84936998777     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.44     Document Type: Article

References (51)

1. Radich JP. Molecular classification of acute myeloid leukemia: are we there yet? J. Clin. Oncol. 26(28), 4539-4541 (2008).
2. O'Donnell MR, Abboud CN, Altman J et al. Acute myeloid leukemia. J. Natl Compr. Canc. Netw. 10(8), 984-1021 (2012).
3. Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5-triphosphate and response to therapy. Cancer Res. 39(1), 42-49 (1979).
4. Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64(1), 54-58 (1984).
5. Galmarini CM, Thomas X, Calvo F et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res. 26(7), 621-629 (2002).
6. Hubeek I, Stam RW, Peters GJ et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 93(12), 1388-1394 (2005).
7. Galmarini CM, Thomas X, Graham K et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br. J. Haematol. 122(1), 53-60 (2003).
8. Galmarini CM, Thomas X, Calvo F et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 117(4), 860-868 (2002).
9. Demontis S, Terao M, Brivio M, Zanotta S, Bruschi M, Garattini E. Isolation and characterization of the gene coding for human cytidine deaminase. Biochim. Biophys. Acta 1443(3), 323-333 (1998).
10. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br. J. Haematol. 103(4), 1096-1103 (1998).
11. Jahns-Streubel G, Reuter C, Auf Der Landwehr U et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factorbased priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 90(5), 1968-1976 (1997).
12. Ciccolini J, Evrard A, M'batchi L et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 13(4), 393-397 (2012).
13. Abraham A, Devasia AJ, Varatharajan S, Karathedath S, Balasubramanian P, Mathews V. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Ann. Hematol. 94(5), 883-885 (2014).
14. Galmarini CM, Graham K, Thomas X et al. Expression of high Km 5-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98(6), 1922-1926 (2001).
15. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4731-4737 (2006).
16. Schwind S, Marcucci G, Kohlschmidt J et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 118(15), 4188-4198 (2011).
17. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2006, 169-177 (2006).
18. Cilloni D, Renneville A, Hermitte F et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J. Clin. Oncol. 27(31), 5195-5201 (2009).
19. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 14(3), 467-473 (2000).
20. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5), 937-951 (2009).
21. Korf BR. Overview of clinical cytogenetics. Curr. Protoc. Hum. Genet. Chapter 8, Unit 8. 1 (2001).
22. Jin G, Matsushita H, Asai S et al. FLT3-ITD induces Ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem. Biophys. Res. Commun. 390(3), 1001-1006 (2009).
23. Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 21(24), 4642-4649 (2003).
24. Abraham A, Varatharajan S, Abbas S et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3), 269-282 (2012).
25. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, CA, USA, 2009. https://bmsr. usc. edu
26. Hartford CM, Duan S, Delaney SM et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009).
27. Parihar M, Kumar JA, Sitaram U et al. Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis. Leuk. Lymphoma 53(1), 103-109 (2012).
28. Yamamoto Y, Kiyoi H, Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8), 2434-2439 (2001).
29. Van Dongen JJ, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 13(12), 1901-1928 (1999).
30. Philip C, George B, Ganapule A et al. Acute myeloid leukaemia: challenges and real world data from India. Br. J. Haematol. doi:10. 1111/bjh. 13406 (2015) (Epub ahead of print).
31. Dumontet C, Fabianowska-Majewska K, Mantincic D et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. 106(1), 78-85 (1999).
32. Drahovsky D, Kreis W. Studies on drug resistance. II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-beta-D-arabinofuranosylcytosine. Biochem. Pharmacol. 19(3), 940-944 (1970).
33. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 44(11), 5029-5037 (1984).
34. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin. Pharmacokinet. 41(2), 93-103 (2002).
35. Kroep JR, Loves WJ, Van Der Wilt CL et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1(6), 371-376 (2002).
36. Stam RW, Den Boer ML, Meijerink JP et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101(4), 1270-1276 (2003).
37. Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66(7), 3928-3935 (2006).
38. Braess J, Pfortner J, Kern W, Hiddemann W, Schleyer E. Cytidine deaminase-the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann. Hematol. 78(11), 514-520 (1999).
39. Ciccolini J, Dahan L, Andre N et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28(1), 160-165 (2010).
40. Bhatla D, Gerbing RB, Alonzo TA et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144(3), 388-394 (2009).
41. Mahlknecht U, Dransfeld CL, Bulut N et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 23(10), 1929-1932 (2009).
42. Galmarini CM, Cros E, Thomas X, Jordheim L, Dumontet C. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica 90(12), 1699-1701 (2005).
43. Li L, Schaid DJ, Fridley BL et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet. Genomics 22(2), 105-116 (2012).
44. Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120(6), 1355-1363 (2007).
45. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64(11), 3761-3766 (2004).
46. Bepler G, Sharma S, Cantor A et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(10), 1878-1885 (2004).
47. Xie H, Jiang W, Jiang J et al. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer 119(1), 173-181 (2013).
48. Cao X, Mitra AK, Pounds S et al. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics 14(12), 1449-1466 (2013).
49. PharmGKB database. www. pharmgkb. org
50. Mullighan CG, Kennedy A, Zhou X et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 21(9), 2000-2009 (2007).
51. Computational Biology Research Consortium: TF search. www. cbrc. jp/research/db/TFSEARCH. html